SAS and UNC-Chapel Hill partner to accelerate antiviral drug development

SAS, a leader in analytics and software services, and the University of North Carolina at Chapel Hill are teaming up to transform the drug development process to prevent infectious disease threats from turning into a pandemic like COVID-19. The partnership is focused on the work of the University’s Rapidly Emerging Antiviral Drug Development Initiative, which is developing broad spectrum antiviral drugs to have on the shelf to prevent future pandemics.

Author: Mike Jackson